Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
Onconetix, Inc. filed a Current Report on Form 8-K under Item 8.01, Other Events. The report concerns the Company’s continued listing status on The Nasdaq Capital Market. The earliest reported event date was March 27, 2024; the filing was signed April 8, 2024.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Material Change Versus Prior Period
- Nasdaq previously notified the Company that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- The initial 180-day compliance period was scheduled to expire on March 16, 2024.
- On March 13, 2024, the Company submitted a compliance plan to Nasdaq that included the potential use of a reverse stock split.
- On March 27, 2024, Nasdaq granted the Company an additional 180-day compliance period, extending the deadline to September 16, 2024.
Outlook, Risks, and Contingencies
- The Company must regain compliance with the $1.00 minimum bid requirement by September 16, 2024.
- If compliance is not regained, Nasdaq staff is expected to issue notice that the common stock is subject to delisting.
- The Company may request a hearing before the Nasdaq Hearings Panel. A timely request would stay further suspension or delisting action pending the hearing process and any Panel-granted extension.
- There is no assurance that an appeal would be successful, that the Company will regain compliance, or that it will maintain compliance with other Nasdaq listing requirements.
- The Company stated that it will monitor the closing bid price and consider available measures, including potentially effecting a reverse stock split.
Investor Verification Points
- Verify whether ONCO regained compliance with Nasdaq’s minimum bid price requirement by September 16, 2024.
- Verify whether the Company authorized or completed a reverse stock split and review its effect on shareholders and the trading price.
- Check for subsequent Nasdaq notices, hearing results, delisting actions, or additional extensions.
- Review subsequent periodic filings for the Company’s financial condition, liquidity, capital needs, and other Nasdaq listing requirements.